High demand has pushed another Novo Nordisk weight loss drug into shortage.
Saxenda (liraglutide) 6 milligram/milliliter, 3 milliliter solutions will be in limited supply for the rest of 2023, according to a July 18 FDA post.
Some solutions of Novo Nordisk's other chronic weight management drug, Wegovy (semaglutide), have been in shortage for more than a year because of high demand. In May, the drugmaker curbed its output of lower dose strengths to ensure and meet drug quality standards.
The company estimated the Wegovy shortage will recover in October.
Ozempic, a Novo Nordisk Type 2 diabetes drug popular for its off-label use for weight loss, has also experienced unsteady supply levels for months.